News | July 21, 2023
Tillotts Pharma and TVM Capital form Mage Biologics to develop oral antibody therapy for ulcerative colitis
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
The agreement extends the customer's suite of cloud DevOps, data engineering, and data platform management solutions
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
Advances clinical research capabilities with leading regulatory grade registries platform
_256_384.jpg)
The collaboration aims to raise awareness about eye cancer, provide medical and surgical treatment support to children and supply nutritional supplements to aid in their faster recovery.
This four-day course is designed for professionals in the pharmaceutical, nutraceutical, and related industries
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
Subscribe To Our Newsletter & Stay Updated
